Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 459 across all filing types
Latest filing 2024-04-03 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2024
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly return report on movements in securities for Ocumension Therapeutics, including authorized share capital, issued shares, share options, warrants, and other share-related movements. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content focuses on share capital changes and confirmations related to securities issuance, without financial statements or earnings data. It is a regulatory compliance filing related to share capital movements rather than a financial report or announcement of voting results. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length and detail confirm it is the report itself, not just an announcement of a report.
2024-04-03 English
(I) PROPOSED AMENDMENTS TO THE 2021 SHARE OPTION SCHEME&#x3b; AND (II) PROPOSED AMENDMENTS TO THE 2021 SHARE AWARD SCHEME
Regulatory Filings Classification · 95% confidence The document is an announcement from Ocumension Therapeutics regarding proposed amendments to their 2021 Share Option Scheme and 2021 Share Award Scheme. It details the key changes to these share schemes and states that these amendments will be subject to shareholders' approval at a general meeting. The document is a formal announcement of proposed changes to share schemes and the intention to seek shareholder approval, rather than the actual circular or proxy materials sent to shareholders or the final approval results. It does not contain financial statements or detailed financial data, nor is it a report or presentation. It is not a regulatory certification or a report publication announcement. The content fits best with a Regulatory Filings (RNS) category, as it is a regulatory announcement about corporate governance matters related to share schemes and shareholder meetings, but not a full governance report or proxy solicitation material. Therefore, the classification is RNS with high confidence.
2024-03-21 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Annual Report Classification · 95% confidence The document is titled 'ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023' and contains detailed audited consolidated annual results, business highlights, financial highlights, corporate profile, and management discussion and analysis for the full fiscal year 2023. It includes comprehensive financial data, operational updates, and strategic outlook, which are typical contents of an Annual Report. The document is lengthy (15,000 characters) and contains substantive financial and operational information, not merely an announcement or summary. Therefore, it fits the definition of an Annual Report (10-K). FY 2023
2024-03-21 English
VOLUNTARY ANNOUNCEMENT PRIMARY ENDPOINTS ACHIEVED IN THE PHASE II CLINICAL TRIAL OF OT-202
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ocumension Therapeutics regarding the achievement of primary endpoints in a Phase II clinical trial for a drug (OT-202). It provides business updates and clinical trial progress but does not contain financial statements, detailed financial analysis, or regulatory filings related to financial performance. The document is relatively short (3250 characters) and serves as a business update announcement rather than a formal financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not related to capital/financing, management changes, voting results, or legal proceedings. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2024-03-14 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a notice from the Board of Directors of Ocumension Therapeutics announcing the date of a board meeting scheduled for March 21, 2024. The purpose of the meeting includes considering and approving the annual results for the year ended December 31, 2023, and the recommendation for payment of a final dividend. The document does not contain the actual annual results or financial data but is an announcement of the meeting where these results will be considered and published. The document length is short (1439 characters), and it serves as a notification rather than the report itself. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement rather than an Annual Report (10-K) or Notice of Dividend Amount (DIV).
2024-03-07 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 29 February 2024
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly return report on movements in securities for Ocumension Therapeutics, including authorized share capital, issued shares, share options, warrants, and other share-related movements. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The document does not contain financial statements or earnings data but focuses on share capital and securities issuance details. It is a regulatory filing related to share capital movements rather than a financial report or announcement of voting results. Given the detailed nature and regulatory context, this fits best under the category of Share Issue/Capital Change (SHA). The document is not a brief announcement but a substantive report on share capital changes for the month ended 29 February 2024.
2024-03-01 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.